Supplementary Tables 1-3, Figures 1-2 from Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors

Abstract

<p>Supplementary Tables 1-3, Figures 1-2. Table 1. IC50 values (μM) of gefitinib (A) and erlotinib (B) toward wild type and L858R EGFR. Table 2. IC50 (μM) of gefitinib (A) and erlotinib (B) toward downstream signaling proteins in 32D cells. Table 3. IC50 (μM) of gefitinib (A) and erlotinib (B) toward downstream signaling proteins in cancer cell lines. Figure 1. (A) Effect of gefitinib on activation of EGFR signaling proteins in 32D cells. (B) Effect of erlotinib on activation of EGFR signaling proteins in 32D cells. Figure 2. (A) Effect of gefitinib on activation of EGFR signaling proteins in cancer cells. (B) Effect of erlotinib on activation of EGFR signaling proteins in cancer cells.</p>